Medical robotics could produce the next Nvidia because it’s following the exact playbook that made Nvidia dominant in AI: become the foundational infrastructure that everyone else builds upon. Just as Nvidia’s GPUs became essential to every major AI advancement, the company that supplies the computing, sensors, and software stack for surgical robots stands to capture outsized value across an entire ecosystem. Consider Intuitive Surgical’s da Vinci system—with over 8,000 units installed globally and more than 12 million procedures performed, it demonstrates how a single platform can generate recurring revenue, network effects, and switching costs that compound for decades. The timing is particularly acute right now. The global surgical robotics market reached USD 16.07 billion in 2026 and is projected to expand to USD 63.73 billion by 2035, growing at a 16.54% compound annual growth rate.
Meanwhile, Nvidia itself just announced a comprehensive robotics strategy in March 2026, including the Isaac GR00T N1 foundation model, the Newton physics engine (developed with Google DeepMind and Disney Research), and the Jetson T4000 module powered by Blackwell GPUs. This isn’t speculation—it’s a company with proven infrastructure expertise entering a market where demand is accelerating faster than supply, regulation, or existing capacity can keep up. The medical robotics market is fundamentally different from consumer robotics because it’s driven by regulatory approval, hospital capital expenditure, and clinical outcomes rather than retail trends. That creates a moat. It also means the winner isn’t just the robot manufacturer—it’s the company that controls the technology layer underneath them.
Table of Contents
- WHY THE SURGICAL ROBOTICS MARKET IS EXPANDING SO RAPIDLY
- THE INFRASTRUCTURE LAYER THAT NVIDIA IS BUILDING
- MARKET LEADERSHIP AND THE CONSOLIDATION PATTERN
- THE VENTURE CAPITAL WAVE IN MEDICAL ROBOTICS
- THE REGULATORY AND MANUFACTURING BARRIERS THAT PROTECT INCUMBENTS
- NORTH AMERICA’S MARKET DOMINANCE AND THE EXPANSION OPPORTUNITY
- THE LONG-TERM TRAJECTORY AND WHAT “THE NEXT NVIDIA” ACTUALLY MEANS
- Conclusion
WHY THE SURGICAL ROBOTICS MARKET IS EXPANDING SO RAPIDLY
The surgical robotics market is growing at 16.54% annually, which puts it in the same category as high-growth software businesses, not traditional medical device companies. this isn’t hype—it’s driven by a genuine clinical need for minimally invasive surgery, which reduces postoperative pain, shortens hospital stays, accelerates recovery, and lowers complication rates. When a patient spends three days in the hospital instead of seven, and avoids opioid complications, hospitals see measurable cost savings. Surgeons get better ergonomics, precision, and control. Patients recover faster and return to work sooner. This alignment of incentives across stakeholders is rare in healthcare and explains why adoption is accelerating rather than plateauing. The market size tells the story.
The global medical robotics market (including surgical, orthopedic, and therapeutic robots) is forecast to reach USD 72.54 billion by 2035, up from USD 18.32 billion in 2026. That’s not a rounding error—it’s a 4x market expansion in nine years. For comparison, the entire U.S. medical device market grew at about 5-7% annually for the past decade. Medical robotics is outpacing the broader industry by a factor of two to three, which suggests this isn’t a temporary trend but a structural shift in how surgery is performed. However, there’s a critical limitation to keep in mind: this market is heavily concentrated in developed countries, particularly North America, which holds 51% of the global market share. Expansion into emerging markets faces real barriers—cost of the equipment, lack of specialized training infrastructure, and regulatory uncertainty. The USD 72.54 billion forecast assumes successful penetration in markets where these barriers don’t yet exist, which is not guaranteed.
THE INFRASTRUCTURE LAYER THAT NVIDIA IS BUILDING
Nvidia’s advantage in medical robotics is that it’s not trying to build surgical robots—it’s building the foundation that surgical robot companies will use. The Isaac GR00T N1 foundation model and Newton physics engine are software tools that let medical robotics companies train their systems faster, simulate outcomes before deployment, and add AI capabilities without starting from scratch. The Jetson T4000 module with Blackwell GPUs is the compute engine that makes that possible in a form factor small enough to fit in operating room equipment or surgical instruments. This is the infrastructure strategy that worked for Nvidia in gaming (GPUs became essential to every game engine), AI (GPUs became essential to every major model), and data centers (Nvidia became the bottleneck in AI infrastructure). In surgical robotics, Nvidia is trying to become the same kind of bottleneck—the company you need to go through to build anything competitive.
Partners like CMR Surgical, Medtronic, Johnson & Johnson, and PeritasAI are already building on Nvidia technology, which suggests the strategy is gaining traction. Medtronic’s Hugo surgical system, for example, is competing directly with Intuitive’s da Vinci, but both are likely to benefit from advances in Nvidia’s underlying AI and compute capabilities. The limitation here is execution risk and market timing. Nvidia could get product-market fit wrong, or it could face competition from other AI chip manufacturers or open-source alternatives. The medical robotics companies themselves might decide to build proprietary AI stacks rather than rely on Nvidia’s ecosystem. Additionally, regulatory approval in healthcare moves slowly—even if Nvidia’s tools are technically superior, hospital adoption depends on clinical validation and FDA approval, which can take years.
MARKET LEADERSHIP AND THE CONSOLIDATION PATTERN
Intuitive Surgical currently owns the surgical robotics market with its da Vinci system. Over 8,000 units installed, 12 million-plus procedures performed, and decades of clinical data—this is not a startup anymore, it’s entrenched infrastructure. However, the FDA approved several competing surgical systems in the past few years: Hugo (Medtronic), Senhance (Asensus), and orthopedic platforms like Mako (Stryker) and ROSA (Zimmer Biomet). This is the classic pattern of a market maturing: the incumbent remains dominant, but competition forces innovation and price pressure, which accelerates overall market adoption. The parallel to Nvidia is instructive but incomplete. Nvidia became dominant in GPUs not just because it had the best products but because CUDA, its software ecosystem, created switching costs that prevented competitors from gaining traction. In surgical robotics, the equivalent lock-in is the surgeon’s experience and the hospital’s capital investment in one platform.
Training surgeons on a new system takes time and money. Replacing operating room equipment that’s already integrated with hospital workflows is a major decision. This creates stickiness, but it’s not as absolute as CUDA lock-in. A hospital with six da Vinci systems can still add a Hugo system if the clinical outcomes justify it. This competitive dynamic is actually healthy for the overall market because it drives innovation faster than monopolies do. Intuitive is pushing harder on AI, vision, and autonomous suturing. Medtronic is leaning into cost efficiency and ease of use. This competition benefits everyone downstream—including companies like Nvidia that sell to the entire ecosystem.
THE VENTURE CAPITAL WAVE IN MEDICAL ROBOTICS
Money is flowing into medical robotics at unprecedented rates. Robotics startups secured over USD 2.26 billion in Q1 2026 alone, though roughly 70% of that went to warehouse and industrial automation. Medical and surgical robotics raised nearly USD 800 million in 2023, and the trend is accelerating. More significantly, AI companies captured 55% of health tech venture funding in 2025, up from 37% in 2024, making AI the single most important driver of medtech deal flow. This capital influx is creating a virtuous cycle: more funding accelerates research and prototyping, which shortens the time from concept to clinical validation, which reduces the risk for hospital adoption, which increases market size.
It’s the same dynamic that made AI infrastructure companies like Nvidia, Anthropic, and others valuable in the first place—not because of current revenue, but because investors believed in exponential growth curves in markets that were barely forming. The tradeoff is that not all this capital will generate returns. Many of these startups will fail, face regulatory setbacks, or find that the clinical economics don’t work as expected. Medical robotics requires FDA approval, which adds 2-5 years to the timeline from prototype to revenue. It also requires hospital capital budgets, which are constrained and conservative. Some brilliant startup technology will never make it past a clinical trial or reimbursement negotiation.
THE REGULATORY AND MANUFACTURING BARRIERS THAT PROTECT INCUMBENTS
Here’s where the Nvidia comparison breaks down: medical robotics faces regulatory hurdles that GPUs never did. Every surgical system has to go through FDA approval, which involves extensive clinical trials, safety documentation, and validation studies. This process took Medtronic roughly 10 years and hundreds of millions in R&D before Hugo achieved FDA approval. That’s not a bug in the system—it’s a feature. We want surgery robots to be heavily scrutinized because the stakes are human lives. This regulatory barrier is actually a moat for whoever wins the market. Once Intuitive Surgical got FDA approval for da Vinci, the company benefited from 20+ years of clinical data, surgeon familiarity, and hospital integration.
New competitors have to run their own trials from scratch, which costs money and time. Nvidia can accelerate the software and AI components, but it can’t bypass the clinical trials. This means medical robotics will consolidate more slowly than traditional tech markets, and the incumbent advantages will persist longer. Manufacturing scale is another barrier. Building 1,000 surgical robots per year requires precision manufacturing, supply chain management, and quality control that rivals automotive and aerospace equipment. This isn’t just software—it’s complex hardware with mechanical and electrical components that have to work perfectly in a sterile environment. Startups excel at innovation, but scaling manufacturing to meet global demand is where large, established companies have advantages.
NORTH AMERICA’S MARKET DOMINANCE AND THE EXPANSION OPPORTUNITY
North America holds 51% of the global surgical robotics market share as of 2025 and is expected to maintain leadership through 2035. This concentration reflects high healthcare expenditure, advanced hospital infrastructure, strong surgeon training programs, and regulatory frameworks that reward innovation. The United States in particular has a culture of early adoption in medicine—hospitals compete on having the latest technology, and patients expect cutting-edge treatment options. This dominance also creates an expansion opportunity.
The other 49% of the market—Europe, Asia-Pacific, Latin America, and emerging markets—is growing faster than North America in percentage terms, even if absolute dollar volumes are smaller. China and India have massive patient populations, rising healthcare budgets, and lower labor costs that could make robotic surgery more economically viable than in developed countries. A single company that can adapt its technology for these markets and navigate different regulatory frameworks could capture enormous value. This is where a well-capitalized infrastructure provider like Nvidia has advantages over a single robot manufacturer—it can work with local partners and adapt its software stack more easily than a hardware company can redesign its entire product line.
THE LONG-TERM TRAJECTORY AND WHAT “THE NEXT NVIDIA” ACTUALLY MEANS
The question “why medical robotics could produce the next Nvidia” is really asking: which company will capture the majority of the economic value in this market? The answer might not be a surgical robot manufacturer at all. It could be the AI platform provider (like Nvidia), the simulation software company, the sensor manufacturer, or the cloud platform that trains and distributes surgical AI models. History suggests that in complex ecosystems, value consolidates at the platform layer, not at the application layer. If the surgical robotics market reaches USD 63-72 billion by 2035, and if one company captures 20-30% of the economic value through platform, software, or infrastructure, that’s USD 12-20 billion in annual revenue potential.
Nvidia’s current data center revenue is over USD 120 billion annually, but a decade ago it was much smaller. A company that dominates medical robotics infrastructure could achieve Nvidia-scale valuations and influence in the next 10-15 years. The key variable is whether that company is Nvidia itself, a specialized medical AI company, or a healthcare IT platform. The technology is proven, the market is real, and the adoption curve is accelerating. The winner just hasn’t been fully determined yet.
Conclusion
Medical robotics could produce the next Nvidia because it’s a large, growing market with high barriers to entry, strong incumbent advantages, and a critical need for AI, simulation, and compute infrastructure. The market is expanding at 16.54% annually, driven by genuine clinical benefits and hospital economics that favor minimally invasive surgery. More importantly, the market’s structure—with regulatory complexity, hardware manufacturing challenges, and AI-driven innovation—creates opportunities for platform companies to capture outsized value by becoming essential to everyone else’s success. The next five years will be pivotal.
FDA approvals for new systems will compete with Intuitive Surgical’s entrenched position. Venture capital will fund dozens of startups, most of which will fail. Nvidia and other AI infrastructure companies will deepen their partnerships with hospital systems and robot manufacturers. The outcome will depend on which company best understands that the real value in medical robotics isn’t the robots themselves—it’s the intelligence that makes them safer, faster, and smarter than human surgeons. That’s where the Nvidia moment lives.
